US EditionActithera Joins Radiopharmaceutical Boom with $75.5M Series A - Boston ...
OSLO, NORWAY AND CAMBRIDGE, MASSACHUSETTS, JUL 9 – Actithera secured $75.5 million in an oversubscribed Series A round led by M Ventures and others to prepare clinical development of its FAP-targeted cancer drug starting in 2026.
- On July 9, 2025, Actithera, a radiopharmaceutical biotech firm headquartered in Oslo and Cambridge, successfully secured $75.5 million in a heavily subscribed Series A funding round.
- The funding round was jointly led by M Ventures along with new leading investors specializing in life sciences, providing support for the clinical progression of the company’s primary candidate targeting fibroblast activation protein .
- Actithera develops small-molecule radioligands designed to improve tumor targeting, extend tumor residence, and enable rapid clearance to reduce toxicity in radioligand therapies .
- Dr. Andreas Goutopoulos explained that their goal was to apply principles from small-molecule drug development, focusing on structural and kinetic insights, to enhance the design of radiopharmaceutical therapies.
- The funding will allow Actithera to advance clinical trials starting in 2026 across multiple oncology indications, reflecting growing investor confidence in radiopharmaceutical therapies.
Insights by Ground AI
Does this summary seem wrong?
12 Articles
12 Articles
All
Left
Center
5
Right
PR NewswireReposted by 
Eastern Progress
Eastern ProgressActithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube...
·United States
Read Full Article
Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy - PressReach
Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor Capital and others Led by founder and drug discovery expert Dr. Andreas Goutopoulos, Actithera’s proprietary three-pillar discovery platform is designed to enable prolonged radioligand tumor retention Proceeds will support clinical development of Actithera’s fibroblast …
Coverage Details
Total News Sources12
Leaning Left0Leaning Right0Center5Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
